



MTB/INH RT-PCR Assay Kit

CE

 **heyer**

Tuberculosis (TB) is a communicable disease that is a major cause of ill health and one of the leading causes of death worldwide. An estimated 10.6 million people fell ill with TB in 2021, an increase of 4.5% from 10.1 million in 2020. The burden of drug-resistant TB (DR-TB) is also estimated to have increased between 2020 and 2021

The use of molecular nucleic acid amplification tests (NAATs) test is recommended for TB detection.

—Global Tuberculosis Report 2020 of the WHO

Clinical value

Drug-resistant tuberculosis (DR-TB) is prevalent globally, and the problem of isoniazid resistance is becoming increasingly serious. The MTB/INH Real-Time PCR Assay is used for in vitro qualitative detection of Mycobacterium tuberculosis complex and isoniazid resistance gene (MTB/INH) in human sputum (BALL,CSF) samples. This detection covers 50%-80% of isoniazid resistance mutations, assisting early clinical diagnosis and precise treatment.

Strengths



Accurate

Integrated with magnetic bead extraction + RT-qPCR
Sample Processing Control



Rapid

Complete whole process of extraction and amplification in 90 min



Simple

Fully-Automated
Total hands-on time : 2 minutes



Lyophilization

Lyophilized reagents stable at room temperature for 12 months

MTB/INH Real-Time PCR Assay

Methodology:	RT-PCR	Limit-of-detection	100 CFU/mL
Pathogens	MTBC,INH	CV	≤5 %
Targets	IS6110,KatG,inhA	TAT	90 min
Sample type	Sputum,BALL,CSF	Internal standard	Sample Processing Control (SPC)
Storage	4 °C~ 30 °C for up to 12 months	Specification	12 tests/kit



Heyer Biotech GmbH

Carl-Heyer-Str. 1/3, 56130 Bad Ems, Germany

sales@heyarmed.com

www.heyerbiotech.de